Personensuche
Personensuche
Es wurde 1 Person gefunden.
Aktuelle Veranstaltungen
-
WiSe 2025
Vergangene Veranstaltungen (max. 10)
-
SoSe 2025
- Hämatologisches und onkologisches Mittagsseminar
- Blockpraktikum Innere Medizin (PV)
- Kurs der allgemeinen klinischen Untersuchungen (PV)
- Innere Medizin für Studierende im Praktischen Jahr (*)
- Innere Medizin Vorlesung, Teil 1 (WA)
- Wahlfach: Cancer Biology
- Differentialdiagnose Innere Krankheiten
- Pathophysiologie (WA)
- E3 - Med - Cancer Biology - Cr. 3-3
-
WiSe 2024
Die folgenden Publikationen sind in der Online-Universitätsbibliographie der Universität Duisburg-Essen verzeichnet. Weitere Informationen finden Sie gegebenenfalls auch auf den persönlichen Webseiten der Person.
-
CSF1R⁺ myeloid-monocytic cells drive CAR-T cell resistance in aggressive B cell lymphomaIn: Cancer Cell, Jg. 43, 2025, Nr. 8, S. 1476 – 1494.e10DOI (Open Access)
-
Cardiac biomarkers for risk stratification in newly diagnosed high-risk multiple myeloma in the GMMG-CONCEPT trialIn: Cardio-Oncology, Jg. 11, 2025, Nr. 1, 63DOI (Open Access)
-
Correction to: ECP versus ruxolitinib in steroid-refractory chronic GVHD : A retrospective study by the EBMT transplant complications working partyIn: Bone Marrow Transplantation, Jg. 60, 2025, Nr. 1, S. 114DOI (Open Access)
-
Eμ-TCL1 mice with conditional human BCL2 knockin as novel B-cell lymphoma model for studying venetoclax effects in vivoIn: Blood Neoplasia, Jg. 2, 2025, Nr. 4, 100143DOI (Open Access)
-
Functional synapses between neurons and small cell lung cancerIn: Nature, Jg. 646, 2025, Nr. 8087, S. 1243 – 1253DOI (Open Access)
-
Gain or amplification of 1q21 in systemic light chain amyloidosis is associated with advanced Mayo stage, plasma cell disease and worse overall survivalIn: Annals of Hematology, Jg. 104, 2025, Nr. 3, S. 1777 – 1788DOI, Online Volltext (Open Access)
-
Gemtuzumab ozogamicin in first-line treatment of CBF-AML : Insights from a retrospective multi-center analysisIn: Leukemia, Jg. 39, 2025, Nr. 9, S. 2174 – 2180DOI (Open Access)
-
Imaging mass cytometry dataset of small-cell lung cancer tumors and tumor microenvironmentsIn: BMC Research Notes, Jg. 18, 2025, 385DOI (Open Access)
-
Outcome of Patients with IDH-mutated AML following Allogeneic Stem Cell Transplantation : a Retrospective Analysis on behalf of the German Registry for Hematopoietic Stem Cell Transplantation and Cell Therapy, DRSTIn: Transplantation and Cellular Therapy, Jg. 31, 2025, Nr. 5, S. 303.e1 – 303.e9DOI (Open Access)
-
Patient:innen mit Krebs als Herausforderung in der NotaufnahmeIn: Medizinische Klinik - Intensivmedizin und Notfallmedizin, Jg. 120, 2025, Nr. 7, S. 541 – 545DOI (Open Access)
-
Pilot Study of Low-Dose Splenic Irradiation and Transplantation in JAK Inhibitor-Refractory Myelofibrosis With SplenomegalyIn: Transplantation and Cellular Therapy, Jg. 31, 2025, Nr. 9, S. 693.e1 – 693.e9DOI (Open Access)
-
Publisher Correction : Functional synapses between neurons and small cell lung cancerIn: Nature, Jg. 646, 2025, Nr. 8086, S. E17DOI (Open Access)
-
Risk beyond neutropenia : insights into neutrophil migration from newly diagnosed AML until late after allogeneic stem cell transplantationIn: Journal of Leukocyte Biology (JLB), Jg. 117, 2025, Nr. 2, qiae250
-
Role of molecular alterations in transplantation decisions for patients with primary myelofibrosisIn: Blood Advances, Jg. 9, 2025, Nr. 4, S. 797 – 807DOI (Open Access)
-
Single-Center Experience of Patients with Plasma Cell Leukemia in the Era of New TherapeuticsIn: Acta Haematologica, Jg. 148, 2025, Nr. 1, S. 77 – 84
-
Single-cell analysis of a bi-clonal chronic lymphocytic leukemia reveals two clones with distinct gene expression patternIn: Leukemia and Lymphoma, Jg. 66, 2025, Nr. 4, S. 744 – 752DOI (Open Access)
-
TAT-CRE inhalation enables tumor induction corresponding to adenoviral Cre-recombinase in a lung cancer mouse modelIn: Communications Biology, Jg. 8, 2025, Nr. 1, 741DOI (Open Access)
-
Treosulfan-Based Conditioning Ameliorates the Impact of Pretransplantation Measurable Residual Disease-Positivity in Acute Myeloid Leukemia Patients Allografted in RemissionIn: Transplantation and Cellular Therapy, 2025, in pressDOI (Open Access)
-
Was ist gesichert in der Therapie des diffusen großzelligen B-Zell-Lymphoms?In: Die Innere Medizin, 2025, in press
-
Why implementing machine learning algorithms in the clinic is not a plug-and-play solution : A simulation study of a machine learning algorithm for acute leukaemia subtype diagnosisIn: eBioMedicine, Jg. 111, 2025, 105526DOI (Open Access)
-
A novel mouse model recapitulating the MMR-defective SCLC subtype uncovers an actionable sensitivity to immune checkpoint blockadeIn: Journal of Cancer Research and Clinical Oncology, Jg. 150, 2024, Nr. 11, 496DOI (Open Access)
-
An anti-CD19/CTLA-4 switch improves efficacy and selectivity of CAR T cells targeting CD80/86-upregulated DLBCLIn: Cell Reports Medicine, Jg. 5, 2024, Nr. 2, 101421DOI (Open Access)
-
An inducible Cd79b mutation confers ibrutinib sensitivity in mouse models of Myd88-driven diffuse large B-cell lymphomaIn: Blood Advances, Jg. 8, 2024, Nr. 5, S. 1063 – 1074DOI (Open Access)
-
Anti-T-lymphocyte globulin improves GvHD-free and relapse-free survival in myelofibrosis after matched related or unrelated donor transplantationIn: Bone Marrow Transplantation, Jg. 59, 2024, Nr. 8, S. 1154 – 1160DOI (Open Access)
-
Autologous-allogeneic versus autologous tandem stem cell transplantation and maintenance therapy with thalidomide for multiple myeloma patients under 60 years of age : a prospective, phase II studyIn: Haematologica / The Hematology Journal, Jg. 109, 2024, Nr. 5, S. 1469 – 1479DOI (Open Access)
-
Blocking the angiopoietin-2-dependent integrin β-1 signaling axis abrogates small cell lung cancer invasion and metastasisIn: JCI Insight, Jg. 9, 2024, Nr. 10DOI (Open Access)
-
CDK9 inhibition as an effective therapy for small cell lung cancerIn: Cell Death and Disease, Jg. 15, 2024, Nr. 5, 345DOI (Open Access)
-
Crizanlizumab in adult patients with sickle cell disease: : a retrospective German analysisIn: Frontiers in Hematology, Jg. 3, 2024, 1374181DOI, Online Volltext (Open Access)
-
Daratumumab in first-line treatment of patients with light chain amyloidosis and Mayo stage IIIb improves treatment response and overall survivalIn: Haematologica / The Hematology Journal, Jg. 109, 2024, Nr. 1, S. 220 – 230DOI (Open Access)
-
ECP versus ruxolitinib in steroid-refractory chronic GVHD : A retrospective study by the EBMT transplant complications working partyIn: Bone Marrow Transplantation, Jg. 59, 2024, Nr. 3, S. 380 – 386DOI (Open Access)
-
Entirely noninvasive outcome prediction in central nervous system lymphomas using circulating tumor DNAIn: Blood, Jg. 143, 2024, Nr. 6, S. 522 – 534
-
Establishing Medical Intelligence - Leveraging Fast Healthcare Interoperability Resources to Improve Clinical Management : Retrospective Cohort and Clinical Implementation StudyIn: Journal of Medical Internet Research (JMIR), Jg. 26, 2024, e55148DOI, Online Volltext (Open Access)
-
Evolutionary trajectories of small cell lung cancer under therapyIn: Nature, Jg. 627, 2024, Nr. 8005, S. 880 – 889DOI (Open Access)
-
How to optimize the CAR-T Cell therapy process? : A group concept mapping analysis of preconditions for a frictionless process from a German multistakeholder perspectiveIn: Frontiers in Oncology, Jg. 14, 2024, 1466803DOI (Open Access)
-
Hypercalcemia as a rare manifestation of immune reconstitution inflammatory syndrome (IRIS) in a person living with Human Immunodeficiency Virus (HIV) with disseminated nontuberculous mycobacteriosisIn: Infection - A Journal of Infectious Disease, Jg. 52, 2024, Nr. 4, S. 1627 – 1631DOI (Open Access)
-
Isatuximab, Carfilzomib, Lenalidomide, and Dexamethasone for the Treatment of High-Risk Newly Diagnosed Multiple MyelomaIn: Journal of Clinical Oncology (JCO), Jg. 42, 2024, Nr. 1, S. 26 – 37DOI (Open Access)
-
Multicenter development of a PET-based risk assessment tool for product-specific outcome prediction in large B-cell lymphoma patients undergoing CAR T-cell therapyIn: European Journal of Nuclear Medicine and Molecular Imaging, Jg. 51, 2024, Nr. 5, S. 1361 – 1370DOI (Open Access)
-
Noninvasive minimal residual disease assessment in relapsed/refractory large B-cell lymphoma using digital droplet PCRIn: European Journal of Haematology, Jg. 112, 2024, Nr. 6, S. 957 – 963DOI (Open Access)
-
Outcomes of CMML patients undergoing allo-HCT are significantly worse compared to MDS : A study of the CMWP of the EBMTIn: American Journal of Hematology, Jg. 99, 2024, Nr. 2, S. 203 – 215DOI (Open Access)
-
Plain language summary of isatuximab plus carfilzomib, lenalidomide, and dexamethasone for the treatment of people with high-risk newly diagnosed multiple myelomaIn: Future Oncology, Jg. 20, 2024, Nr. 39, S. 3193 – 3207DOI (Open Access)
-
Proteomic analysis of pleomorphic dermal sarcoma reveals a fibroblastic cell of origin and distinct immune evasion mechanismsIn: Scientific Reports, Jg. 14, 2024, Nr. 1, 12516DOI, Online Volltext (Open Access)
-
Splenic irradiation for myelofibrosis prior to hematopoietic cell transplantation : A global collaborative analysisIn: American Journal of Hematology, Jg. 99, 2024, Nr. 5, S. 844 – 853DOI (Open Access)
-
Time-dependent cost comparison and health economic impact analysis of second-line interventions for transplant-ineligible patients with relapsed or refractory diffuse large B cell lymphomaIn: European Journal of Haematology, Jg. 113, 2024, Nr. 3, S. 371 – 383DOI (Open Access)
-
XPO1-Mediated mRNA Export of Genome Maintenance Regulators Drives Chemotherapy Resistance in Aggressive LymphomaIn: Cancer Research, Jg. 84, 2024, Nr. 1, S. 3 – 5
-
Allogeneic hematopoietic stem cell transplantation for NK/T-cell lymphoma : An international collaborative analysisIn: Leukemia, Jg. 37, 2023, Nr. 7, S. 1511 – 1520DOI (Open Access)
-
Author Correction: Interleukin 17 signaling supports clinical benefit of dual CTLA-4 and PD-1 checkpoint inhibition in melanomaIn: Nature Cancer, Jg. 4, 2023, Nr. 9, S. 1395DOI (Open Access)
-
Characteristics and outcome of patients with acute myeloid leukemia and trisomy 4In: Haematologica / The Hematology Journal, Jg. 108, 2023, Nr. 1, S. 34 – 41DOI (Open Access)
-
Corneal confocal microscopy identifies corneal nerve loss and increased Langerhans cells in presymptomatic carriers and patients with hereditary transthyretin amyloidosisIn: Journal of Neurology, Jg. 270, 2023, Nr. 7, S. 3483 – 3491DOI (Open Access)
-
Cost-effectiveness analysis of transplant-ineligible relapsed or refractory diffuse large B-cell lymphoma treatment options : Experience of the efficiency frontier approachIn: European Journal of Haematology, Jg. 111, 2023, Nr. 6, S. 895 – 908DOI (Open Access)
-
Data-driven grading of acute graft-versus-host diseaseIn: Nature Communications, Jg. 14, 2023, Nr. 1, 7799DOI, Online Volltext (Open Access)
-
Distinct genetically-determined origins of Myd88/Bcl2-driven aggressive lymphoma rationalize targeted therapeutic intervention strategiesIn: Blood Cancer Discovery, Jg. 4, 2023, Nr. 1, S. 78 – 97DOI (Open Access)
-
Dose-dependent expression of GFI1 alters metabolism in the haematopoietic progenitors and MLL::AF9-induced leukaemic cellsIn: British Journal of Haematology, Jg. 202, 2023, Nr. 5, S. 1033 – 1048DOI (Open Access)
-
Fludarabine/TBI 8 Gy versus fludarabine/treosulfan conditioning in patients with AML in first complete remission : a study from the Acute Leukemia Working Party of the EBMTIn: Bone Marrow Transplantation, Jg. 58, 2023, Nr. 6, S. 710 – 716DOI (Open Access)
-
Germ line variant GFI1-36N affects DNA repair and sensitizes AML cells to DNA damage and repair therapyIn: Blood, Jg. 142, 2023, Nr. 25, S. 2175 – 2191DOI (Open Access)
-
Hemizygous CDKN2A deletion confers worse survival outcomes in IDHmut-noncodel gliomasIn: Neuro-Oncology, Jg. 25, 2023, Nr. 9, S. 1721 – 1723DOI (Open Access)
-
Impact of BMI on patient outcome in acute myeloid leukaemia patients receiving intensive induction therapy : A real-world registry experienceIn: British Journal of Cancer (BJC), Jg. 129, 2023, Nr. 7, S. 1126 – 1133DOI (Open Access)
-
Impact of TP53 on outcome of patients with myelofibrosis undergoing hematopoietic stem cell transplantationIn: Blood, Jg. 141, 2023, Nr. 23, S. 2901 – 2911DOI (Open Access)
-
Integrating biological HLA-DPB1 mismatch models to predict survival after unrelated hematopoietic cell transplantationIn: Haematologica / The Hematology Journal, Jg. 108, 2023, Nr. 2, S. 645 – 652DOI (Open Access)
-
Intensified cytarabine dose during consolidation in adult AML patients under 65 years is not associated with survival benefit : Real-world data from the German SAL-AML registryIn: Journal of Cancer Research and Clinical Oncology, Jg. 149, 2023, Nr. 8, S. 4611 – 4621DOI (Open Access)
-
Interleukin 17 signaling supports clinical benefit of dual CTLA-4 and PD-1 checkpoint inhibition in melanomaIn: Nature Cancer, Jg. 4, 2023, Nr. 9, S. 1292 – 1308DOI (Open Access)
-
Intratumoral Abundance of M2-Macrophages is Associated With Unfavorable Prognosis and Markers of T-Cell Exhaustion in Small Cell Lung Cancer PatientsIn: Modern Pathology, Jg. 36, 2023, Nr. 10, 100272DOI (Open Access)
-
Mouse models of diffuse large B cell lymphomaIn: Frontiers in Immunology, Jg. 14, 2023, 1313371DOI, Online Volltext (Open Access)
-
Outcome Prediction in Patients With Large B-cell Lymphoma Undergoing Chimeric Antigen Receptor T-cell TherapyIn: HemaSphere: Open Access Journal of the European Hematology Association, Jg. 7, 2023, Nr. 1, S. E817DOI (Open Access)
-
Patient-tailored adoptive immunotherapy with EBV-specific T cells from related and unrelated donorsIn: The Journal of Clinical Investigation (JCI), Jg. 133, 2023, Nr. 12, e163548DOI (Open Access)
-
Predicting HPV association using deep learning and regular H&E stains allows granular stratification of oropharyngeal cancer patientsIn: npj Digital Medicine, Jg. 6, 2023, Nr. 1, 152DOI, Online Volltext (Open Access)
-
Somatic rearrangements causing oncogenic ectodomain deletions of FGFR1 in squamous cell lung cancerIn: The Journal of Clinical Investigation (JCI), Jg. 133, 2023, Nr. 21, e174171DOI (Open Access)
-
Time series clustering of T cell subsets dissects heterogeneity in immune reconstitution and clinical outcomes among MUD-HCT patients receiving ATG or PTCyIn: Frontiers in Immunology, Jg. 14, 2023, 1082727DOI, Online Volltext (Open Access)
-
20-Year Steady Increase in Survival of Adult Patients with Relapsed Philadelphia-Positive Acute Lymphoblastic Leukemia Post Allogeneic Hematopoietic Cell TransplantationIn: Clinical Cancer Research, Jg. 28, 2022, Nr. 5, S. 1004 – 1012DOI (Open Access)
-
Aberrant expansion of spontaneous splenic germinal centers induced by hallmark genetic lesions of aggressive lymphomaIn: Blood, Jg. 140, 2022, Nr. 10, S. 1119 – 1131DOI (Open Access)
-
Acquired aplastic anemia following SARS-CoV-2 vaccinationIn: European Journal of Haematology, Jg. 109, 2022, Nr. 2, S. 186 – 194DOI (Open Access)
-
CD74-NRG1 Fusions Are Oncogenic In Vivo and Induce Therapeutically Tractable ERBB2:ERBB3 HeterodimerizationIn: Molecular Cancer Therapeutics, Jg. 21, 2022, Nr. 5, S. 821 – 830DOI (Open Access)
-
Combined inhibition of EZH2 and ATM is synthetic lethal in BRCA1-deficient breast cancerIn: Breast Cancer Research, Jg. 24, 2022, Nr. 1, 41DOI (Open Access)
-
Corneal confocal microscopy to detect early immune-mediated small nerve fibre loss in AL amyloidosisIn: Annals of Clinical and Translational Neurology, Jg. 9, 2022, Nr. 6, S. 853 – 863DOI, Online Volltext (Open Access)
-
Correction to: Impact of conditioning regimen intensity on outcomes of second allogeneic hematopoietic cell transplantation for secondary acute myelogenous leukemiaIn: Bone Marrow Transplantation, Jg. 57, 2022, Nr. 12, 1854DOI (Open Access)
-
Deregulation and epigenetic modification of BCL2-family genes cause resistance to venetoclax in hematologic malignanciesIn: Blood, Jg. 140, 2022, Nr. 20, S. 2113 – 2126DOI (Open Access)
-
Early report on the severity of COVID-19 in hematologic patients infected with the SARS-CoV2 omicron variantIn: European Journal of Haematology, Jg. 109, 2022, Nr. 4, S. 364 – 372DOI (Open Access)
-
Extracellular vesicles and PD-L1 suppress macrophages, inducing therapy resistance in TP53-deficient B-cell malignanciesIn: Blood, Jg. 139, 2022, Nr. 25, S. 3617 – 3629DOI (Open Access)
-
High Molecular and Cytogenetic Risk in Myelofibrosis Does Not Benefit from Higher Intensity Conditioning before Hematopoietic Cell Transplantation : An International Collaborative AnalysisIn: HemaSphere: Open Access Journal of the European Hematology Association, Jg. 6, 2022, Nr. 10, E784DOI (Open Access)
-
Impact of conditioning regimen intensity on outcomes of second allogeneic hematopoietic cell transplantation for secondary acute myelogenous leukemiaIn: Bone Marrow Transplantation, Jg. 57, 2022, Nr. 7, S. 1116 – 1123
-
Interim FDG-PET analysis to identify patients with aggressive non-Hodgkin lymphoma who benefit from treatment intensification : A post-hoc analysis of the PETAL trialIn: Leukemia, Jg. 36, 2022, Nr. 12, S. 2845 – 2852DOI (Open Access)
-
Isatuximab, carfilzomib, lenalidomide, and dexamethasone (Isa-KRd) in front-line treatment of high-risk multiple myeloma : Interim analysis of the GMMG-CONCEPT trialIn: Leukemia, Jg. 36, 2022, Nr. 3, S. 885 – 888DOI (Open Access)
-
Luspatercept, a two‐edged sword in beta‐thalassemia‐associated paravertebral extramedullary hematopoietic masses (EHMs)In: European Journal of Haematology, Jg. 109, 2022, Nr. 6, S. 664 – 671DOI (Open Access)
-
Mitochondrial Kv1.3 Channels as Target for Treatment of Multiple MyelomaIn: Cancers, Jg. 14, 2022, Nr. 8, 1955DOI, Online Volltext (Open Access)
-
Preneoplastic somatic mutations including MYD88L²⁶⁵P in lymphoplasmacytic lymphomaIn: Science Advances, Jg. 8, 2022, Nr. 3, eabl4644DOI (Open Access)
-
Prevalence and predictors of neurological manifestations in systemic AL amyloidosisIn: Journal of the Neurological Sciences, Jg. 440, 2022, 120341
-
Reduced intensity hematopoietic stem cell transplantation for accelerated-phase myelofibrosisIn: Blood Advances, Jg. 6, 2022, Nr. 4, S. 1222 – 1231DOI (Open Access)
-
SHMT2 inhibition disrupts the TCF3 transcriptional survival program in Burkitt lymphomaIn: Blood, Jg. 139, 2022, Nr. 4, S. 538 – 553DOI (Open Access)
-
Screening and diagnosis of hemoglobinopathies in Germany: Current state and future perspectivesIn: Scientific Reports, Jg. 12, 2022, Nr. 1, 9762DOI, Online Volltext (Open Access)
-
Tripartite antigen-agnostic combination immunotherapy cures established poorly immunogenic tumorsIn: Journal for ImmunoTherapy of Cancer, Jg. 10, 2022, Nr. 10, e004781DOI (Open Access)
-
Active Akt signaling triggers CLL toward Richter transformation via overactivation of Notch1In: Blood, Jg. 137, 2021, Nr. 5, S. 646 – 660DOI (Open Access)
-
Adaptive T-cell immunity controls senescence-prone MyD88- or CARD11-mutant B-cell lymphomasIn: Blood, Jg. 137, 2021, Nr. 20, S. 2785 – 2799DOI (Open Access)
-
Altered DNA methylation profiles in SF3B1 mutated CLL patientsIn: International Journal of Molecular Sciences (IJMS), Jg. 22, 2021, Nr. 17, 9337DOI (Open Access)
-
An Autochthonous Mouse Model of Myd88- and BCL2-Driven Diffuse Large B-cell Lymphoma Reveals Actionable Molecular VulnerabilitiesIn: Cancer Discovery, Jg. 2, 2021, Nr. 1, S. 70 – 91DOI, Online Volltext (Open Access)
-
Biallelic variants in YRDC cause a developmental disorder with progeroid featuresIn: Human Genetics, Jg. 140, 2021, Nr. 12, S. 1679 – 1693DOI (Open Access)
-
Deep Learning Predicts HPV Association in Oropharyngeal Squamous Cell Carcinomas and Identifies Patients with a Favorable Prognosis Using Regular H&E StainsIn: Clinical Cancer Research, Jg. 27, 2021, Nr. 4, S. 1131 – 1138DOI (Open Access)
-
Factor IX p.A37V mutation causes severe bleeding in a patient with phenprocoumon therapyIn: European Journal of Medical Research, Jg. 26, 2021, Nr. 1, 63DOI, Online Volltext (Open Access)
-
Ferroptosis response segregates small cell lung cancer (SCLC) neuroendocrine subtypesIn: Nature Communications, Jg. 12, 2021, Nr. 1, 2048DOI (Open Access)
-
Humoral and cellular vaccination responses against sars-cov-2 in hematopoietic stem cell transplant recipientsIn: Vaccines, Jg. 9, 2021, Nr. 10, 1075DOI (Open Access)
-
Impact of time to diagnosis on Mayo stages, treatment outcome, and survival in patients with AL amyloidosis and cardiac involvementIn: European Journal of Haematology, Jg. 107, 2021, Nr. 4, S. 449 – 457DOI (Open Access)
-
Low Soluble Programmed Cell Death Protein 1 Levels After Allogeneic Stem Cell Transplantation Predict Moderate or Severe Chronic GvHD and Inferior Overall SurvivalIn: Frontiers in Immunology, Jg. 12, 2021, 694843DOI, Online Volltext (Open Access)
-
Pericentromeric Satellite III transcripts induce etoposide resistanceIn: Cell Death and Disease, Jg. 12, 2021, Nr. 6, 530DOI (Open Access)
-
Pregnancies and neonatal outcomes in patients with sickle cell disease (SCD) : Still a (high-)risk constellation?In: Journal of Personalized Medicine, Jg. 11, 2021, Nr. 9, 870DOI, Online Volltext (Open Access)
-
Proteomic and bioinformatic profiling of neutrophils in CLL reveals functional defects that predispose to bacterial infectionsIn: Blood Advances, Jg. 5, 2021, Nr. 5, S. 1259 – 1272DOI (Open Access)
-
Targeting CD38 in acute myeloid leukemia interferes with leukemia trafficking and induces phagocytosisIn: Scientific Reports, Jg. 11, 2021, Nr. 1, 22062DOI, Online Volltext (Open Access)
-
Texture analysis of iodine maps and conventional images for k-nearest neighbor classification of benign and metastatic lung nodulesIn: Cancer Imaging, Jg. 21, 2021, Nr. 1, 17DOI (Open Access)
-
Thymic hyperplasia after mRNA based Covid-19 vaccinationIn: Radiology Case Reports, Jg. 16, 2021, Nr. 12, S. 3744 – 3745DOI (Open Access)
-
Trends in allogeneic haematopoietic cell transplantation for myelofibrosis in Europe between 1995 and 2018: a CMWP of EBMT retrospective analysisIn: Bone Marrow Transplantation, Jg. 56, 2021, S. 2160 – 2172DOI, Online Volltext (Open Access)
-
Acute myeloid leukemia–induced remodeling of the human bone marrow niche predicts clinical outcomeIn: Blood Advances, Jg. 4, 2020, Nr. 20, S. 5257 – 5268DOI (Open Access)
-
Economic Impact of the Introduction of Outpatient Medical Specialist Care (ASV) of Gastrointestinal Cancer Patients from a German Hospital Management PerspectiveIn: Oncology Research and Treatment, Jg. 43, 2020, Nr. 10, S. 498 – 505
-
Integrative Analysis of Pleomorphic Dermal Sarcomas Reveals Fibroblastic Differentiation and Susceptibility to ImmunotherapyIn: Clinical Cancer Research, Jg. 26, 2020, Nr. 21, S. 5638 – 5645DOI (Open Access)
-
Meta-analysis reveals significant sex differences in chronic lymphocytic leukemia progression in the eµ-tcl1 transgenic mouse modelIn: Cancers, Jg. 12, 2020, Nr. 7, 1980DOI (Open Access)
-
Mutations in PIGA cause a CD52-/GPI-anchor-deficient phenotype complicating alemtuzumab treatment in T-cell prolymphocytic leukemiaIn: European Journal of Haematology, Jg. 105, 2020, Nr. 6, S. 786 – 796DOI (Open Access)
-
mTOR-mediated cancer drug resistance suppresses autophagy and generates a druggable metabolic vulnerabilityIn: Nature Communications, Jg. 11, 2020, Nr. 1, 4684DOI (Open Access)
-
Exosome-dependent immune surveillance at the metastatic niche requires BAG6 and CBP/p300-dependent acetylation of p53In: Theranostics, Jg. 9, 2019, Nr. 21, S. 6047 – 6062DOI (Open Access)
-
UBQLN4 Represses Homologous Recombination and Is Overexpressed in Aggressive TumorsIn: Cell, Jg. 176, 2019, Nr. 3, S. 505 – 519.e22DOI (Open Access)
-
Two mouse models reveal an actionable PARP1 dependence in aggressive chronic lymphocytic leukemiaIn: Nature Communications, Jg. 8, 2017, Nr. 1, 153DOI (Open Access)
-
B-cell-specific conditional expression of Myd88p.L²⁵²P leads to the development of diffuse large B-cell lymphoma in miceIn: Blood, Jg. 127, 2016, Nr. 22, S. 2732 – 2741DOI (Open Access)
-
Ercc1 Deficiency Promotes Tumorigenesis and Increases Cisplatin Sensitivity in a Tp53 Context-Specific MannerIn: Molecular Cancer Research, Jg. 14, 2016, Nr. 11, S. 1110 – 1123
-
A Synergistic Interaction between Chk1- and MK2 Inhibitors in KRAS-Mutant CancerIn: Cell, Jg. 162, 2015, Nr. 1, S. 146 – 159DOI (Open Access)
-
Comprehensive genomic profiles of small cell lung cancerIn: Nature, Jg. 524, 2015, Nr. 7563, S. 47 – 53DOI (Open Access)
-
Erratum: A Synergistic Interaction between Chk1- and MK2 Inhibitors in KRAS-Mutant CancerIn: Cell, Jg. 162, 2015, Nr. 5, S. 1169DOI (Open Access)
-
Hypoxia-induced p38 MAPK activation reduces Mcl-1 expression and facilitates sensitivity towards BH3 mimetics in chronic lymphocytic leukemiaIn: Leukemia, Jg. 29, 2015, Nr. 4, S. 981 – 984
-
A functional cancer genomics screen identifies a druggable synthetic lethal interaction between MSH3 and PRKDCIn: Cancer Discovery, Jg. 4, 2014, Nr. 5, S. 592 – 605DOI (Open Access)
-
Therapeutic targeting of a robust non-oncogene addiction to PRKDC in ATM-defective tumorsIn: Science Translational Medicine, Jg. 5, 2013, Nr. 189, S. 189ra78
-
Cytokine-Induced Signaling Networks Prioritize Dynamic Range over Signal StrengthIn: Cell, Jg. 135, 2008, Nr. 2, S. 343 – 354DOI (Open Access)
-
14-3-3σ controls mitotic translation to facilitate cytokinesisIn: Nature, Jg. 446, 2007, Nr. 7133, S. 329 – 332
-
p53-Deficient Cells Rely on ATM- and ATR-Mediated Checkpoint Signaling through the p38MAPK/MK2 Pathway for Survival after DNA DamageIn: Cancer Cell, Jg. 11, 2007, Nr. 2, S. 175 – 189DOI (Open Access)
-
An Aged/Autoimmune B-cell Program Defines the Early Transformation of Extranodal LymphomasIn: Cancer Discovery. Philadelphia: American Association for Cancer Research (AACR), Jg. 13, 2023, Nr. 1, S. 216 – 243DOI, Online Volltext (Open Access)
-
Editorial: Exploiting DNA Damage Response in the Era of Precision OncologyIn: Frontiers in Oncology. Lausanne: Frontiers Media, Jg. 10, 2020, 611127DOI (Open Access)
-
Association of Cardiac Biomarkers and Adverse Events with a Carfilzomib-Containing Quadruplet in High-Risk Newly Diagnosed Multiple Myeloma Patients: Correlative Program of the GMMG-CONCEPT Trial
21st Annual Meeting and Exposition of the International Myeloma Society, 25-28 September 2024, Rio de Janeiro, Brazil,In: Clinical Lymphoma, Myeloma & Leukemia. New York: Elsevier, Jg. 24, 2024, Nr. Suppl. 2, S. S12 – S13 -
CRISPR-TOF Platform : A Single-Cell Approach for Studying Kinase-Dependent Immune-Signaling Dynamics in Human Primary T Cells
The 66th ASH Annual Meeting, December 7-10, 2024, San Diego, USA,In: Blood. Washington; New York, NY [u.a.]; Philadelphia, Pa.: American Society of Hematology, Jg. 144, 2024, Nr. Supplement 1, S. 1060DOI (Open Access) -
Characterizing and Targeting Follicular Lymphoma's Common Progenitor Cells
66th ASH Annual Meeting, December 7-10, 2024, San Diego, CA, USA,In: Blood. Washington; New York, NY [u.a.]; Philadelphia, Pa.: American Society of Hematology, Jg. 144, 2024, Nr. Supplement 1, S. 2745 – 2745DOI (Open Access) -
Deciphering ERBB2-driven mechanisms that regulate tumor immune evasion and metastasis in SCLC
ESMO Congress 2024, 13-17 September 2024, Barcelona, Spain,In: Annals of Oncology. Amsterdam: Elsevier, Jg. 35, 2024, Nr. Suppl. 2, S. S1066 – S1067 -
Gain or Amplification of 1q21 in Systemic Light Chain Amyloidosis Is Associated with Advanced Mayo Stage, Plasma Cell Disease and Worse Overall SurvivalIn: Blood. The 66th ASH Annual Meeting, December 7-10, 2024, San Diego, USA: American Society of Hematology, Jg. 144, 2024, Nr. Supplement 1, S. 3309DOI (Open Access)
-
Idecabtagene Vicleucel (ide-cel) Shows Similar Efficacy and Toxicity in Patients with Multiple Myeloma Aged 70 and Older Compared to Younger Patients : A Multicenter Cohort Study
The 66th ASH Annual Meeting, December 7-10, 2024, San Diego, USA,In: Blood. Washington; New York, NY [u.a.]; Philadelphia, Pa.: American Society of Hematology, Jg. 144, 2024, Nr. Supplement 1, S. 3383DOI (Open Access) -
Isa-KRd in High-Risk Newly Diagnosed Multiple Myeloma : 4-Year-Follow-Up from the GMMG-CONCEPT trial
21st Annual Meeting and Exposition of the International Myeloma Society, 25-28 September 2024, Rio de Janeiro, Brazil,In: Clinical Lymphoma, Myeloma & Leukemia. New York: Elsevier, Jg. 24, 2024, Nr. Suppl. 2, S. S33 – S34 -
Outcome after Allogeneic Stem Cell Transplant in Adults with Inherited Myeloid Malignancies : a Multicenter Retrospective Analysis on Behalf of the German Cooperative Transplant Study Group
The 66th ASH Annual Meeting, December 7-10, 2024, San Diego, USA,In: Blood. Washington; New York, NY [u.a.]; Philadelphia, Pa.: American Society of Hematology, Jg. 144, 2024, Nr. Supplement 1, S. 2179DOI (Open Access) -
Personalized Transplant Decision Making for Myelofibrosis in the Era of Molecular Genetics and JAK InhibitionIn: Blood. Washington; New York, NY [u.a.]; Philadelphia, Pa.: American Society of Hematology, Jg. 144, 2024, Nr. Supplement 1, S. 245 – 245DOI (Open Access)
-
ATG/ATLG Improves GvHD-Free and Relapse-Free Survival in Myelofibrosis Undergoing Hematopoietic Stem Cell TransplantationIn: Blood. Washington; New York, NY [u.a.]; Philadelphia, Pa.: American Society of Hematology, Jg. 142, 2023, Nr. Supplement 1: Annual Meeting Abstracts (65th ASH Annual Meeting and Exposition, 9-12 Dezember 2023, San Diego), S. 3572 – 3572DOI (Open Access)
-
Allogeneic hematopoietic stem cell transplantation achieves long-term survival in Natural killer/T-cell lymphoma in the era of Asparaginase-based Chemotherapy
Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie ; 13. bis 16. Oktober 2023, Hamburg, Germany,In: Oncology Research and Treatment. Basel: Karger, Jg. 46, 2023, Nr. Supplement 5: DGHO Abstracts, S. 104 – 105DOI (Open Access) -
An In Vivo PiggyBac Insertional Mutagenesis Screen Reveals Oncogenic Lesions Cooperating with Myd88 L265P
65th ASH Annual Meeting, December 9-12, 2023, San Diego, CA, USA,In: Blood. Washington; New York, NY [u.a.]; Philadelphia, Pa.: American Society of Hematology, Jg. 142, 2023, Nr. Supplement 1, S. 525 – 526DOI (Open Access) -
Investigation of cardiac biomarkers and association with clinical course under treatment with a carfilzomib containing quadruplet regimen in high-risk newly diagnosed multiple myeloma patients : results from the correlative program of the GMMG-CONCEPT trial
Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie ; 13. bis 16. Oktober 2023, Hamburg, Germany,In: Oncology Research and Treatment. Basel: Karger, Jg. 46, 2023, Nr. Supplement 5: DGHO Abstracts, S. 32 – 33DOI (Open Access) -
Planned Interim Analysis of the GMMG-CONCEPT Trial investigating Isatuximab, Carfilzomib, Lenalidomide, and Dexamethasone (Isa-KRd) in Patients with High-Risk Newly Diagnosed Multiple Myeloma
Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie ; 13. bis 16. Oktober 2023, Hamburg, Germany,In: Oncology Research and Treatment. Basel: Karger, Jg. 46, 2023, Nr. Supplement 5: DGHO Abstracts, S. 55 – 56DOI (Open Access) -
Prognostic factors for cellular therapies ‐ CART and allogeneic SCT ‐ in relapsed /refractory large B cell lymphoma (LBCL)
17th International Conference on Malignant Lymphoma, 13 ‐ 17 June, 2023, Lugano, Switzerland,In: Hematological Oncology. Hoboken: Wiley-Blackwell - STM, Jg. 41, 2023, Nr. S2, 17th International Conference on Malignant Lymphoma, Palazzo dei Congressi, Lugano, Switzerland, 13 - 17 June, 2023, S. 449 – 451DOI (Open Access) -
Allogeneic Hematopoietic Stem Cell Transplantation Achieves Long-Term Survival in Extranodal Natural Killer/T-Cell Lymphoma : A Retrospective Analysis of the EBMT Lymphoma Working Party
64th Annual Meeting and Exposition of the American Society of Hematology ; December 10 - 13, 2022, New Orleans,In: Blood. Washington; New York, NY [u.a.]; Philadelphia, Pa.: American Society of Hematology, Jg. 140, 2022, Nr. Supplement 1: 64th Annual Meeting, S. 2306 – 2307DOI (Open Access) -
Combined inhibition of EZH2 and ATM is synthetic lethal in BRCA1-deficient breast cancer
64. Kongress der Deutschen Gesellschaft für Gynäkologie und Geburtshilfe, 12.–15.10.2022, München, Germany,In: Geburtshilfe und Frauenheilkunde. Stuttgart: Thieme, Jg. 82, 2022, Nr. 10, S. e146 -
Glomerular Fitration Rate and Lactate Dehydrogenase Predicts Survival in Mayo Iiib Stage Light-Chain Amyloidosis
64th ASH Annual Meeting, December 10-13, 2022, New Orleans, LA, USA,In: Blood. Washington; New York, NY [u.a.]; Philadelphia, Pa.: American Society of Hematology, Jg. 140, 2022, Nr. Supplement 1: 64th Annual Meeting, S. 12571 – 12572DOI (Open Access) -
Isatuximab, Carfilzomib, Lenalidomide, and Dexamethasone (Isa-KRd) in Patients with High-Risk Newly Diagnosed Multiple Myeloma : Planned Interim Analysis of the GMMG-Concept Trial
64th Annual Meeting and Exposition of the American Society of Hematology ; December 10 - 13, 2022, New Orleans, LA, USA,In: Blood. Washington; New York, NY [u.a.]; Philadelphia, Pa.: American Society of Hematology, Jg. 140, 2022, Nr. Supplement 1, S. 1836 – 1838DOI (Open Access) -
Luspatercept bei Patienten mit transfusionsabhängiger β-Thalassämie : die erste reale Analyse
Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie, 7.–10. Oktober 2022, Wien, Austria,In: Oncology Research and Treatment. Basel: Karger, Jg. 45, 2022, Nr. Supplement 2, S. 49DOI (Open Access) -
Metabolic Tumor Volume for Outcome Prediction in Patients with Large B-Cell Lymphoma Undergoing Chimeric Antigen Receptor T-Cell Treatment
EANM‘22 ; 35th Annual Congress of the European Association of Nuclear Medicine ; October 15-19, 2022, Barcelona, Spain,In: European Journal of Nuclear Medicine and Molecular Imaging. Berlin: Springer, Jg. 49, 2022, Nr. Supplement 1, S. S211DOI (Open Access) -
Noninvasive, Dynamic Risk Profiling of Primary Central Nervous System Lymphoma By Peripheral Blood Ctdna-Sequencing
64th ASH Annual Meeting, December 10-13, 2022, New Orleans, LA, USA,In: Blood. Washington; New York, NY [u.a.]; Philadelphia, Pa.: American Society of Hematology, Jg. 140, 2022, Nr. Suppl. 1, S. 3537 – 3538DOI (Open Access) -
Novel Autochthonous Mouse Models of Serve As Preclinical Tools to Investigate Pathogenesis and Treatment of MCD/C5 DLBCL
64th ASH Annual Meeting and Exposition, 10-13 December 2022, New Orleans, LA, USA,In: Blood. Washington; New York, NY [u.a.]; Philadelphia, Pa.: American Society of Hematology, Jg. 140, 2022, Nr. Supplement 1: 64th ASH Annual Meeting Abstracts, S. 3493 – 3494DOI (Open Access) -
Phänotyp von TP53 und Einfluss auf Outcome nach allogener Stammzelltransplantation bei Myelofibros
Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie, 7.–10. Oktober 2022, Wien, Austria,In: Oncology Research and Treatment. Basel: Karger, Jg. 45, 2022, Nr. Supplement 2, S. 80DOI (Open Access) -
Stem cell boost for persistent cytopenia after chimeric antigen receptor t-cell therapy : A German Lymphoma alliance (GLA) study
48th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), March 19-23, 2022, Virtual,In: Bone Marrow Transplantation. London: Springer Nature, Jg. 57, 2022, Nr. Suppl. 1, S. 30 – 31Online Volltext (Open Access) -
Venetoclax and Hypomethylating Agents Followed by Allogeneic Stem Cell Transplantation in Patients with Acute Myeloid Leukemia
64th Annual Meeting and Exposition of the American Society of Hematology ; December 10 - 13, 2022, New Orleans,In: Blood. Washington; New York, NY [u.a.]; Philadelphia, Pa.: American Society of Hematology, Jg. 140, 2022, Nr. Supplement 1: 64th Annual Meeting, S. 12943 – 12944DOI (Open Access) -
Voxelotor bei Jugendlichen und Erwachsenen mit Sichelzellkrankheit : erste Erfahrungen aus dem deutschen Härtefallprogramm
Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie, 7.–10. Oktober 2022, Wien, Austria,In: Oncology Research and Treatment. Basel: Karger, Jg. 45, 2022, Nr. Supplement 2, S. 48DOI (Open Access) -
An autochthonous mouse model provides a rational for combined BTK and BCL2 inhibition in MYD88-mutant diffuse large B cell lymphoma
Gemeinsame Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie ; 01.-04. Oktober 2021, Hybrid-Kongress,In: Oncology Research and Treatment. Basel: Karger, Jg. 44, 2021, Nr. Supplement 2, S. 127DOI (Open Access) -
Characteristics and Outcome of Patients with Acute Myeloid Leukemia and Trisomy 4
63rd ASH Annual Meeting and Exposition, 11-14 December 2021, Atlanta, GA, USA,In: Blood. Washington; New York, NY [u.a.]; Philadelphia, Pa.: American Society of Hematology, Jg. 138, 2021, Nr. Supplement 1: 63rd ASH Annual Meeting Abstracts, S. 1307 – 1310DOI (Open Access) -
Comparative Analysis of Immune Reconstitution In HSCT Patients With PT-CY OR ATG Reveals Distinct T Cell Immune Reconstitution Patterns
47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), 14 – 17 March, 2021, Virtual,In: Bone Marrow Transplantation. London: Springer Nature, Jg. 56, 2021, Nr. Suppl. 1, S. 126Online Volltext (Open Access) -
Retrospective Analysis Evaluating The Effect of Age on Outcomes After Allogeneic Hematopoietic Cell Transplantation In Chronic Myelomonocytic Leukemia : A Study of The EBMT-CMWP
47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), 14–17 March, 2021, Virtual,In: Bone Marrow Transplantation. London: Springer Nature, Jg. 56, 2021, Nr. Suppl. 1, S. 139 – 141Online Volltext (Open Access) -
Trends and Predictive Factors for Outcome of Relapsed Philadelphia Positive Acute Lymphoblastic Leukemia After Allogeneic Hematopoietic Cell Transplantion : Improvement of Survival in Recent Years
47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), 14–17 March, 2021, Virtual,In: Bone Marrow Transplantation. London: Springer Nature, Jg. 56, 2021, Nr. Suppl. 1, S. 23 – 24Online Volltext (Open Access) -
Updated interim analysis of the GMMG-CONCEPT trial investigating Isatuximab, Carfilzomib, Lenalidomide, and Dexamethasone (Isa-KRd) in front-line treatment of high-risk Multiple Myeloma
Gemeinsame Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie ; 01.-04. Oktober 2021, Hybrid-Kongress,In: Oncology Research and Treatment. Basel: Karger, Jg. 44, 2021, Nr. Supplement 2, S. 20 – 21DOI (Open Access) -
Think twice : Anemia of chronic disease (ACD) due to angiomatoid fibrous histiocytoma (AFH)
Virtuelle Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie, 09.–11. Oktober 2020,In: Oncology Research and Treatment. Basel: Karger, Jg. 43, 2020, Nr. Suppl. 4, S. 181DOI (Open Access) -
UBQLN4 represses homologous recombination and is overexpressed in aggressive tumors
Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie, 11. - 14. Oktober 2019, Berlin, Germany,In: Oncology Research and Treatment. Basel: Karger, Jg. 42, 2019, Nr. Supplement 4: Abstracts, S. 25 – 26DOI (Open Access) -
Genetic Mouse Models of LymphomasIn: Lymphoma: Methods and Protocols / Küppers, Ralf (Hrsg.). New York: Humana, 2025, S. 411 – 428
-
Efficacy of Idecabtagene Vicleucel (ide-cel) in Patients with Relapsed/Refractory Multiple Myeloma and Prior Central Nervous System Manifestation: A Retrospective Real-World Analysis
66th ASH Annual Meeting, December 7-10, 2024, San Diego, CA, USA,In: Blood. Washington; New York, NY [u.a.]; Philadelphia, Pa.: American Society of Hematology, Jg. 144, 2024, Nr. Supplement 1, S. 4759 – 4760DOI (Open Access) -
Why Implementing Machine Learning Algorithms in Clinical Routine Is Not a Plug-and-Play Operation : A Simulation Study of a Recently Published ML Algorithm for Acute Leukemia Subtype Diagnosis
The 66th ASH Annual Meeting, December 7-10, 2024, San Diego, USA,In: Blood. Washington; New York, NY [u.a.]; Philadelphia, Pa.: American Society of Hematology, Jg. 144, 2024, Nr. Supplement 1, S. 3592 – 3592DOI (Open Access) -
Intraspinal extramedullary hematopoietic mass (EMH) in a luspatercept-treated patient with transfusion-dependent beta-thalassemia (TDT)
Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie ; 13. bis 16. Oktober 2023, Hamburg, Germany,In: Oncology Research and Treatment. Basel: Karger, Jg. 46, 2023, Nr. Supplement 5: DHGO Abstracts, S. 299 – 300DOI (Open Access) -
New Suitable Eµ-Tcl1 Mouse Model for Research on BH3-Mimetics Therapy Response In Vivo
65th ASH Annual Meeting, December 9-12, 2023, San Diego, CA, USA,In: Blood. Washington; New York, NY [u.a.]; Philadelphia, Pa.: American Society of Hematology, Jg. 142, 2023, Nr. Supplement 1, S. 1454 – 1454DOI (Open Access) -
Predicting HPV-association using regular H&E slides can identify subgroups of patients with favorable prognosis at a highly detailed level
ESMO Congress 2023 ; 20 - 24 October 2023, Madrid, Spain,In: Annals of Oncology. Amsterdam: Elsevier, Jg. 34, 2023, Nr. Supplement 2: Abstract Book of the ESMO Congress 2023, 20 - 24 October 2023, S. S561DOI (Open Access) -
Real-world experience with hypomethylating agents and venetoclax as induction or salvage therapy followed by allogeneic stem cell transplantation in patients with acute myeloid leukemia
Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie ; 13. bis 16. Oktober 2023, Hamburg, Germany,In: Oncology Research and Treatment. Basel: Karger, Jg. 46, 2023, Nr. Supplement 5: DGHO Abstracts, S. 193DOI (Open Access) -
Allele-specific single-nucleotide polymorphisms for NGS-based detection of HLA loss relapses after hematopoietic cell transplantation
Joint 35th European Immunogenetics and Histocompatibility Conference; May 17–20, 2022; Amsterdam, the Netherlands,In: HLA: Immune Response Genetics (Human Leukocyte Antigens). Hoboken: Wiley-Blackwell - STM, Jg. 99, 2022, Nr. 5, SI, S. 487 -
CART Therapy or Allogeneic Stem Cell Transplantation in ≥ Third Line Treatment of Large B Cell Lymphoma (LBCL)
64th Annual Meeting and Exposition of the American Society of Hematology, December 10 - 13, 2022, New Orleans,In: Blood. Washington; New York, NY [u.a.]; Philadelphia, Pa.: American Society of Hematology, Jg. 140, 2022, Nr. Supplement 1: 64th Annual Meeting, S. 7509 – 7511DOI (Open Access) -
Venetoclax-Based Salvage Therapy Improves Outcome in Relapsed/Refractory AML Patients Eligible for Intensive Treatment : A Propensity Score Matching Analysis
64th Annual Meeting and Exposition of the American Society of Hematology, December 10 - 13, 2022, New Orleans,In: Blood. Washington; New York, NY [u.a.]; Philadelphia, Pa.: American Society of Hematology, Jg. 140, 2022, Nr. Supplement 1: 64th Annual Meeting, S. 3317 – 3319DOI (Open Access) -
Low soluble programmed cell death protein 1 levels post allogeneic stem cell transplantation predict extended chronic graft-versus-host disease and inferior overall survival
Gemeinsame Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie ; 01.-04. Oktober 2021, Hybrid-Kongress,In: Oncology Research and Treatment. Basel: Karger, Jg. 44, 2021, Nr. Supplement 2, S. 233DOI (Open Access) -
RICarT : Registry for immune-effector and CAR T associated toxicities
Gemeinsame Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie ; 01.-04. Oktober 2021, Hybrid-Kongress,In: Oncology Research and Treatment. Basel: Karger, Jg. 44, 2021, Nr. Supplement 2, S. 258DOI (Open Access)